Monica Variolo
Research Subjects
Monica Variolo has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Paolo Bossi
3 shared publicationsCarlo Resteghini
2 shared publications- Carlo Resteghini
Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Milan, Italy
2 shared publications - Cristina Gurizzan
Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
2 shared publications - Giuseppe Argenziano
Dermatology Unit, Department of Mental and Physical Health and Preventive Medicine University of Campania Luigi Vanvitelli Naples Italy
2 shared publications - Luigi Lorini
Medical Oncology and Hematology Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Rozzano, Milan, Italy
2 shared publications
Latest Publications
- Open Access
- 6 August 2026
- Published by Elsevier in EJC Skin Cancer
- Vol. 4
From immune activation to pathological response: neoadjuvant immunotherapy in cutaneous squamous cell carcinoma. A systematic review and meta-analysis
- 6 August 2026
- Published by Elsevier in EJC Skin Cancer
- Vol. 4
Open AccessFrom immune activation to pathological response: neoadjuvant immunotherapy in cutaneous squamous cell carcinoma. A systematic review and meta-analysis
- Open Access
- 24 May 2026
- Published by Elsevier in SSRN Electronic Journal
From Immune Activation to Pathological Response: Neoadjuvant Immunotherapy in Cutaneous Squamous Cell Carcinoma. A Systematic Review and Meta-analysis
BackgroundCutaneous squamous cell carcinoma (cSCC) frequently arises in the head and neck region and is associated with significant morbidity when managed with extensive surgery and postoperative radiotherapy. Neoadjuvant immune checkpoint inhibitors (ICI) have emerged as a promising strategy to improve oncologic outcomes while enabling treatment de-escalation.MethodsA systematic review and meta-analysis were conducted to evaluate the efficacy and safety of neoadjuvant ICI in locally advanced (LA) resectable cSCC. Literature from January 2020 to November 2025 was screened across major databases. Eligible prospective studies (≥20 patients) reporting pathological response were included. Pooled estimates of pathological responses were calculated using a random-effects model.ResultsSeven studies (eight cohorts; n=270) were included. The pooled rate of combined clinical complete response (cCR), pathological complete response (pCR), and major pathological response (mPR) was 59.2% (95% CI: 53–65%). The pooled pCR rate was 45.7% (95% CI: 37.7–53.4%). Radiological assessment underestimated response compared to pathology by approximately 50%. Disease control was high, with progression rates ≤5%. Neoadjuvant ICI enabled omission or de-escalation of surgery and/or postoperative radiotherapy in a substantial proportion of responders, with encouraging survival outcomes. Treatment was well tolerated, with rare grade ≥3 adverse events and no significant surgical delays.ConclusionsNeoadjuvant ICI demonstrates high pathological response rates and favorable safety in LA cSCC, supporting its role as a strategy for treatment de-intensification. Pathological response appears to be a reliable surrogate endpoint, whereas conventional imaging remains inadequate.
- 24 May 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessFrom Immune Activation to Pathological Response: Neoadjuvant Immunotherapy in Cutaneous Squamous Cell Carcinoma. A Systematic Review and Meta-analysis
BackgroundCutaneous squamous cell carcinoma (cSCC) frequently arises in the head and neck region and is associated with significant morbidity when managed with extensive surgery and postoperative radiotherapy. Neoadjuvant immune checkpoint inhibitors (ICI) have emerged as a promising strategy to improve oncologic outcomes while enabling treatment de-escalation.MethodsA systematic review and meta-analysis were conducted to evaluate the efficacy and safety of neoadjuvant ICI in locally advanced (LA) resectable cSCC. Literature from January 2020 to November 2025 was screened across major databases. Eligible prospective studies (≥20 patients) reporting pathological response were included. Pooled estimates of pathological responses were calculated using a random-effects model.ResultsSeven studies (eight cohorts; n=270) were included. The pooled rate of combined clinical complete response (cCR), pathological complete response (pCR), and major pathological response (mPR) was 59.2% (95% CI: 53–65%). The pooled pCR rate was 45.7% (95% CI: 37.7–53.4%). Radiological assessment underestimated response compared to pathology by approximately 50%. Disease control was high, with progression rates ≤5%. Neoadjuvant ICI enabled omission or de-escalation of surgery and/or postoperative radiotherapy in a substantial proportion of responders, with encouraging survival outcomes. Treatment was well tolerated, with rare grade ≥3 adverse events and no significant surgical delays.ConclusionsNeoadjuvant ICI demonstrates high pathological response rates and favorable safety in LA cSCC, supporting its role as a strategy for treatment de-intensification. Pathological response appears to be a reliable surrogate endpoint, whereas conventional imaging remains inadequate.
- Open Access
- 29 April 2026
- Published by Elsevier in SSRN Electronic Journal
A phase II, open-label study to improve compliance and time of treatment after obtaining complete response (CR) through a tailored schedule of sonidegib in locally advanced basal cell carcinomas (LA BCC) – the SONIBEC trial
Sonidegib is effective in locally advanced basal cell carcinoma (laBCC) but often causes treatment-related adverse events (TRAEs) that limit continuation. After complete response (CR), discontinuation rates reach up to 60% within one year, with a 3-year relapse-free survival (RFS) of 35%. This study evaluated a tailored schedule (TS) of sonidegib after CR to reduce toxicity and prolong treatment duration.MethodsThis multicenter, open-label, single-arm phase II study enrolled adults with laBCC achieving CR on sonidegib. Patients received TS1 (14 days on/14 days off). Those developing grade 2–3 toxicity (excluding alopecia) lasting >28 days switched to TS2 (7 days on/21 days off). Treatment continued until progression or unacceptable toxicity. Primary endpoint was the proportion of patients maintaining treatment at 12 months (H0 31%, H1 60%). Evaluable patients were those still on treatment or who discontinued for reasons other than TRAEs or death. Secondary endpoints included safety, compliance, RFS, overall survival (OS), quality of life, and resource use.ResultsTwenty-two patients were enrolled; 19 were evaluable. Median follow-up was 35 months. At data cut-off, 74% had discontinued treatment, mainly due to physician/patient choice (32%) or progression (26%). Twelve of 19 patients (63%) remained on treatment at 12 months (median duration 20 months). Median RFS was 34 months, with 1- and 3-year RFS rates of 88% and 46%, respectively. Common TRAEs included muscle cramps, alopecia, fatigue, and dysgeusia; 12 patients required TS2.ConclusionTailored, pulsed sonidegib schedule may extend treatment duration and reduce relapse in laBCC patients with CR. Further follow-up is ongoing.
- 29 April 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessA phase II, open-label study to improve compliance and time of treatment after obtaining complete response (CR) through a tailored schedule of sonidegib in locally advanced basal cell carcinomas (LA BCC) – the SONIBEC trial
Sonidegib is effective in locally advanced basal cell carcinoma (laBCC) but often causes treatment-related adverse events (TRAEs) that limit continuation. After complete response (CR), discontinuation rates reach up to 60% within one year, with a 3-year relapse-free survival (RFS) of 35%. This study evaluated a tailored schedule (TS) of sonidegib after CR to reduce toxicity and prolong treatment duration.MethodsThis multicenter, open-label, single-arm phase II study enrolled adults with laBCC achieving CR on sonidegib. Patients received TS1 (14 days on/14 days off). Those developing grade 2–3 toxicity (excluding alopecia) lasting >28 days switched to TS2 (7 days on/21 days off). Treatment continued until progression or unacceptable toxicity. Primary endpoint was the proportion of patients maintaining treatment at 12 months (H0 31%, H1 60%). Evaluable patients were those still on treatment or who discontinued for reasons other than TRAEs or death. Secondary endpoints included safety, compliance, RFS, overall survival (OS), quality of life, and resource use.ResultsTwenty-two patients were enrolled; 19 were evaluable. Median follow-up was 35 months. At data cut-off, 74% had discontinued treatment, mainly due to physician/patient choice (32%) or progression (26%). Twelve of 19 patients (63%) remained on treatment at 12 months (median duration 20 months). Median RFS was 34 months, with 1- and 3-year RFS rates of 88% and 46%, respectively. Common TRAEs included muscle cramps, alopecia, fatigue, and dysgeusia; 12 patients required TS2.ConclusionTailored, pulsed sonidegib schedule may extend treatment duration and reduce relapse in laBCC patients with CR. Further follow-up is ongoing.